Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Totally Neoadjuvant FOLFOXIRI and XELOX in Rectal Cancer
NCT03484221Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Apr 2018
- Primary completion
- Oct 2021
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, fluorouracil, capecitabine in rectal cancer, sponsored by China Medical University. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatinfluorouracilcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03484221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03484221.